Filtered By:
Condition: Chronic Kidney Disease
Therapy: Dialysis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 325 results found since Jan 2013.

Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4 –5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
AbstractThe role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4 –5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4–5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K ant agonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause dea...
Source: Journal of Thrombosis and Thrombolysis - August 21, 2023 Category: Hematology Source Type: research

Chronic Kidney Disease Is Poised To Become The Black Lung of Climate Change
It’s official. July was the world’s hottest month on record, scientists from the European climate monitoring agency confirmed on Aug. 8, a full 1.5°C (2.7°F) warmer than pre-industrial averages, offering a potent taste of what is to come in a world made hotter by climate change. The wildfires and heat waves that wreathed much of the northern hemisphere in smoke this summer? Expect more of the same. The surge in deaths and hospitalization from heat stress and stroke? Ditto. An increase in chronic kidney disease of non-traditional origin? Yup. Wait, what? [time-brightcove not-tgx=”true”] O...
Source: TIME: Health - August 9, 2023 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized climate change Climate Is Everything healthscienceclimate Source Type: news

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
CONCLUSION: Globally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.PMID:37493856 | DOI:10.1007/s12325-023-02608-9
Source: Adv Data - July 26, 2023 Category: Epidemiology Authors: Vivekanand Jha Saeed M G Al-Ghamdi Guisen Li Mai-Szu Wu Panagiotis Stafylas Lise Retat Joshua Card-Gowers Salvatore Barone Claudia Cabrera Juan Jose Garcia Sanchez Source Type: research

Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease
Conclusion: The cohort study found that in real world practice, among patients with advanced CKD stage V, use of sodium bicarbonate was associated with similar risk of dialysis compared with non-users, Nonetheless, use of sodium bicarbonate was associated with significantly lower rate of MACE and mortality. The study results reinforced the benefits of sodium bicarbonate therapy in the expanding CKD population. Further prospective studies are needed to confirm these findings.
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research

The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease
Int Urol Nephrol. 2023 Feb 16. doi: 10.1007/s11255-023-03500-9. Online ahead of print.ABSTRACTTrimethylamine N-oxide (TMAO) is an intestinal uremic toxin molecule mainly excreted by the kidney. Therefore, the plasma TMAO concentration is significantly increased in chronic kidney disease (CKD) patients, and plasma TMAO can be cleared by dialysis. Furthermore, TMAO damage the kidney mainly through three mechanisms: oxidative stress, inflammation and endoplasmic reticulum stress. Clinical experiments have indicated that higher TMAO levels are strongly related to the elevated incidence and mortality of cardiovascular (CV) even...
Source: Atherosclerosis - February 16, 2023 Category: Cardiology Authors: Sai Pan Delong Zhao Shuwei Duan Xiangmei Chen Source Type: research

Obesity and kidney transplantation
Curr Opin Organ Transplant. 2023 Feb 1. doi: 10.1097/MOT.0000000000001050. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Obesity has reached epidemic proportions in the United States. It is a risk factor for developing, among others, heart disease, stroke, type 2 diabetes, and chronic kidney disease (CKD), and thus a major public health concern and driver of healthcare costs. Although the prevalence of obesity in the CKD/end-stage kidney disease population is increasing, many obese patients are excluded from the benefit of kidney transplant based on their BMI alone. For this reason, we sought to review the experience th...
Source: Current Opinion in Organ Transplantation - February 8, 2023 Category: Transplant Surgery Authors: Jae-Hyung Chang Vladimir Mushailov Sumit Mohan Source Type: research

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionThere was no evidence of increased risk of cardiovascular events or mortality with roxadustat compared with ESA in patients with anemia who have NDD or ID-DD CKD. Although TEAEs occurred commonly in both the roxadustat and ESA groups, patients infrequently discontinued the study drug because of an adverse event.Clinical Trial Registration NumbersDOLOMITES, 1517-CL-0610 [NCT02021318]; HIMALAYAS, FGCL-4592-063 [NCT02052310]; SIERRAS, FGCL-4592-064 [NCT02273726]; and ROCKIES, D5740C00002 [NCT02174731].
Source: Advances in Therapy - February 7, 2023 Category: Drugs & Pharmacology Source Type: research

Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry
CONCLUSION: Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcomes compared to no OAC. ClinicalTrials.gov (NCT02786095).PMID:36579375 | DOI:10.3349/ymj.2022.0455
Source: Yonsei Medical Journal - December 29, 2022 Category: Universities & Medical Training Authors: Hanjin Park Hee Tae Yu Tae-Hoon Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jaemin Shim Jin-Bae Kim Jun Kim Eue-Keun Choi Hyung Wook Park Young Soo Lee Boyoung Joung Source Type: research